Open AccessClinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients1
Author(s) -
Edward Cole,
Nava Maham,
Carl Cardella,
Daniel C. Cattran,
Stanley Fenton,
Jayne Hamel,
Catherine O’Grady,
Robert M. Smith
Publication year - 2003
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000068868.01424.61
Subject(s) - creatinine , medicine , urology , renal function , renal transplant , transplantation , blood pressure , kidney transplantation , kidney , surgery
Cyclosporine monitoring using the 2-hr postdose sample, C2, has been shown to have advantages in monitoring de novo renal transplant recipients. The purpose of this study was to assess cyclosporine exposure, using C2, in stable renal transplant patients previously monitored by C0 to determine the effect of dose reduction on patients with C2 more than 10% above target and the course of those with C2 at and more than 10% below target, whose dose was not modified.